Abstract 1052: Improvement of Plasma Pentraxin3 Following Cardiac Rehabilitation in Patients With Cardiovascular Diseases
[Purposes] Cardiac rehabilitation (CR) has been well known to induce anti-inflammatory effects. Pentraxin3 (PTX3), which belongs to the pentraxin superfamily as C-reactive protein (CRP), is a new serological marker reflecting various types of inflammation as high-sensitive CRP (hsCRP). Therefore, we investigated the effects of CR on plasma PTX3 levels as well as serum hsCRP in patients with cardiovascular diseases.
[Method] 27 patients (64±2 years old) with congestive heart failure and ischemic heart diseases, who had received CR using aerobic bicycle exercise 2–3 times/week, participated in this study. In addition, 9 healthy subjects (40±9 years old) visited the laboratory on 3 times within this study of 4 weeks to observe the inter- and intra-individual coefficient of variation in resting PTX3 and hsCRP level. We analyzed resting plasma PTX3, serum hsCRP, LDL, leptin, and brain natriuretic peptide (BNP) levels. VO2peak and VO2 at aerobic threshold (VO2AT) were determined using a standard increment cycle ergometer protocol. Fluorescence activated cell sorting (FACS) analysis was performed to measure circulating endothelial progenitor cells (EPC).
[Result] In healthy subjects, the inter-and intra-individual coefficient of variation in resting plasma PTX3 level was less than that in serum hsCRP level, suggesting that PTX3 levels were relatively stable. And, there was no significant correlation between resting PTX3 and hsCRP level in patients as well as healthy subjects. Both PTX3 and hsCRP level in patients before CR were significantly higher than those in healthy subjects (P<0.05). The PTX3 level was positively correlated with BNP, VO2AT and VO2peak, but not correlated with LDL and EPC number, and leptin level. The CR for 3–6 months tended to decrease serum hsCRP level, but not statistically significant. On the other hand, CR significantly reduced plasma PTX3 level (P<0.05) time-dependently with a significant improvement in exercise capacity (VO2peak and VO2AT, P<0.05) and BNP (P<0.05).
[Conclusion] These results provide the first evidence showing that plasma PTX3 may become a stable and sensitive marker of effects of CR in patients with cardiovascular diseases, and CR decreases plasma PTX3 level with an improvement of cardiac function.